// App-Quantinova.ai

P6-07-16 : Evaluation of Circulating Tumor Cell as a Marker of Prognosis and Efficacy in a Randomized Phase III Study in HER2 Negative Metastatic Breast Cancer Patients Treated with Capecitabine and Docetaxel: JO21095 Study

Researchers

Presenter

  • Masuda N

Principal Investigators

  • Yamamoto D

  • Sato N

  • Sagara Y

  • Yamamoto Y

  • Saito M

  • Iwata H

  • Oura S

  • Watanabe J

  • Kuroi K

Medical Centers

  • Juntendo University Nerima Hostital, Tokyo, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Wakayama Medical University, Wakayama, Japan

  • Kansai Medical University Hirakata Hospital, Hirakata, Japan

  • National Hospital Organization Toneyama National Hospital, Toyonaka, Japan

  • Niigata Cancer Center Hospital, Niigata City, Japan

  • Sagara Hospital, Kagoshima, Japan

  • Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan.

  • Kyoto University, Kyoto, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved